Evidence map›Paper›PMID 30108314›Full record

ArticleMolecular psychiatry2020

Panic results in unique molecular and network changes in the amygdala that facilitate fear responses.

A I Molosh, E T Dustrude, J L Lukkes, S D Fitz, I F Caliman, A R R Abreu, A D Dietrich, W A Truitt, L Ver Donck, M Ceusters and 3 more

Open access · greenAbstract read
In one paragraph

Article in Molecular psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Advances in translating mGluPharmacology, biochemistry, and behavior · 2022
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

A I MoloshDepartment of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.
E T DustrudeDepartment of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.
J L LukkesDepartment of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.
S D FitzDepartment of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.
I F CalimanDepartment of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
A R R AbreuDepartment of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.
A D DietrichDepartment of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
W A TruittPaul and Carol Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
L Ver DonckJanssen Research & Development, Beerse, Belgium.
M CeustersJanssen Research & Development, Beerse, Belgium.
J M KentJanssen Research & Development, LLC, Titusville, NJ, USA.
P L Johnson *Paul and Carol Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
A Shekhar *Department of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, IN, USA. ashekhar@iu.edu.
Indiana University – Purdue University Indianapolis · USIndiana University School of MedicineJanssen (Belgium) · BEJanssen (United States) · US

Funding

Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
NEUROBIOLOGY OF PANIC AND ANXIETY DISORDERSR01MH052619 · NIMH · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SHEKHAR, ANANTHA · 1996 to 2016
$5.0M
Serotonin and CRF Pathways in Anxiety &HPA RegulationR01MH065702 · NIMH · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI LOWRY, CHRISTOPHER A, SHEKHAR, ANANTHA · 2003 to 2013
$2.8M
Indiana Clinical and Translational Sciences InstituteTL1TR001107 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$2.0M
Hypothalamic Orexin Role in Menopause-Associated Hot Flashes and Mood/Sleep DisruK01AG044466 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI JOHNSON, PHILIP LEE · 2013 to 2016
$467k
NCATS NIH HHS TL1 TR001107NCATS NIH HHS UL1 TR001108NIA NIH HHS K01 AG044466NIMH NIH HHS L30 MH081659NIMH NIH HHS R01 MH052619NIMH NIH HHS R01 MH065702
6 · The paper itself

Abstract

Recurrent panic attacks (PAs) are a common feature of panic disorder (PD) and post-traumatic stress disorder (PTSD). Several distinct brain regions are involved in the regulation of panic responses, such as perifornical hypothalamus (PeF), periaqueductal gray, amygdala and frontal cortex. We have previously shown that inhibition of GABA synthesis in the PeF produces panic-vulnerable rats. Here, we investigate the mechanisms by which a panic-vulnerable state could lead to persistent fear. We first show that optogenetic activation of glutamatergic terminals from the PeF to the basolateral amygdala (BLA) enhanced the acquisition, delayed the extinction and induced the persistence of fear responses 3 weeks later, confirming a functional PeF-amygdala pathway involved in fear learning. Similar to optogenetic activation of PeF, panic-prone rats also exhibited delayed extinction. Next, we demonstrate that panic-prone rats had altered inhibitory and enhanced excitatory synaptic transmission of the principal neurons, and reduced protein levels of metabotropic glutamate type 2 receptor (mGluR2) in the BLA. Application of an mGluR2-positive allosteric modulator (PAM) reduced glutamate neurotransmission in the BLA slices from panic-prone rats. Treating panic-prone rats with mGluR2 PAM blocked sodium lactate (NaLac)-induced panic responses and normalized fear extinction deficits. Finally, in a subset of patients with comorbid PD, treatment with mGluR2 PAM resulted in complete remission of panic symptoms. These data demonstrate that a panic-prone state leads to specific reduction in mGluR2 function within the amygdala network and facilitates fear, and mGluR2 PAMs could be a targeted treatment for panic symptoms in PD and PTSD patients.

Indexed as

AmygdalaAnimalsBasolateral Nuclear ComplexBrainExtinction, PsychologicalFearFrontal LobeGlutamic AcidInhibition, PsychologicalMaleOptogeneticsPanicRatsRats, Sprague-DawleyReceptors, Metabotropic GlutamateSynaptic TransmissionGlutamic Acidmetabotropic glutamate receptor 2Receptors, Metabotropic Glutamate

Identifiers

PMID30108314
PMCPMC6410355
OpenAlexW2885093981

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.